According to Zhu et al. [15], the CD133+CD44+ cells may stand for the true progenitor/cancer stem cells in HCC, which may be a specific target for more efficient treatments and enhance comprehension of progression and initiation in HCC. This evidence concerns the gene PROM1 and hepatocellular carcinoma.